Biocon's Q3 FY 2025-26 Quarterly Results
- 13 Feb 2026
Result Summary
- Biocon Ltd reported a 2.2% quarter-on-quarter (QoQ) decrease in its consolidated revenues for the quarter-ended Dec (Q3 FY 2025-26). On a year-on-year (YoY) basis, it witnessed a growth of 11.3%.
- Its expenses for the quarter were down by 3.3% QoQ and up 9.3% YoY.
- The net profit decreased 139.0% QoQ and decreased 163.9% YoY.
- The earnings per share (EPS) of Biocon Ltd stood at 1.07 during Q3 FY 2025-26.
Financial Statments for Q3 FY 2025-26
Total Income | 4290.30 | 4388.50 | 3856.20 | -2.2% | 11.3% |
Total Expenses | 4064.70 | 4205.30 | 3718.40 | -3.3% | 9.3% |
Profit Before Tax | -67.80 | 171.30 | 155.90 | -139.6% | -143.5% |
Tax | -16.00 | 38.50 | 74.80 | -141.6% | -121.4% |
Profit After Tax | -51.80 | 132.80 | 81.10 | -139.0% | -163.9% |
Earnings Per Share | 1.07 | 0.65 | 0.21 | 64.6% | 409.5% |
Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results
Company Overview
Biocon Ltd is a prominent biopharmaceutical company primarily engaged in the development, manufacture, and marketing of biopharmaceutical products. The company operates in the healthcare and pharmaceuticals industry, focusing on providing innovative solutions in chronic disease areas such as diabetes, oncology, and autoimmune diseases. Biocon is renowned for its expertise in biologics, biosimilars, and generic formulations. The company has a global presence, with its products available in more than 120 countries. While the financial data provided does not include recent major developments, Biocon has been known for its strategic collaborations and investments in research and development to expand its product portfolio.
Revenue
In the third quarter of fiscal year 2026 (Q3FY26), Biocon Ltd reported a total income of ₹4290.30 crores. This represents a quarter-over-quarter (QoQ) decline of 2.2% from the second quarter of fiscal year 2026 (Q2FY26), where the total income was ₹4388.50 crores. On a year-over-year (YoY) basis, there is an 11.3% increase from Q3FY25, when the total income was ₹3856.20 crores. This YoY growth indicates an overall increase in revenue generation compared to the same period last year, despite the recent QoQ decrease.
Profitability
Biocon's financial performance in terms of profitability presents notable fluctuations. The Profit Before Tax (PBT) for Q3FY26 is reported as a negative ₹67.80 crores, a significant decline from the positive ₹171.30 crores in Q2FY26. This represents a QoQ decrease of 139.6%. Compared to Q3FY25, where PBT was ₹155.90 crores, the YoY change is a decline of 143.5%. The Profit After Tax (PAT) for Q3FY26 stands at a negative ₹51.80 crores, contrasting with the positive ₹132.80 crores in Q2FY26, marking a QoQ decrease of 139.0%. On a YoY basis, the PAT has decreased by 163.9% from ₹81.10 crores in Q3FY25. The Earnings Per Share (EPS) for Q3FY26 is ₹1.07, which shows a QoQ increase of 64.6% from ₹0.65 in Q2FY26, and a substantial YoY increase of 409.5% from ₹0.21 in Q3FY25.
Operating Metrics
Total expenses for Biocon in Q3FY26 amounted to ₹4064.70 crores, showing a 3.3% decrease QoQ from ₹4205.30 crores in Q2FY26. However, on a YoY basis, total expenses increased by 9.3% from ₹3718.40 crores in Q3FY25. This indicates an overall increase in operating costs compared to the previous year, despite a reduction from the previous quarter. The tax expense for Q3FY26 is reported as a negative ₹16.00 crores, a sharp decline from ₹38.50 crores in Q2FY26, resulting in a QoQ change of -141.6%. Compared to Q3FY25, where the tax expense was ₹74.80 crores, the YoY change is a decrease of 121.4%. These metrics highlight significant variations in Biocon's operating expenses and tax obligations across the periods examined.